Protagonist Therapeutics to Participate in the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) will participate in the virtual H.C. Wainwright Global Life Sciences Conference from March 9 to 10, 2021. CEO Dinesh V. Patel, Ph.D., will engage in a fireside chat on March 9, starting at 7:00 a.m. EST, with a subsequent opportunity for one-on-one meetings with investors. A webcast of the event will be available for 90 days. Protagonist is advancing multiple peptide-based therapeutics, including PTG-300 and PTG-200, targeting various conditions such as polycythemia vera and Crohn's disease.

NEWARK, Calif., March 2, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and will host one-on-one meetings with investors at the upcoming virtual H.C. Wainwright Global Life Sciences Conference taking place March 9 to March 10, 2021.

Fireside chat details:
Date: Tuesday, March 9, 2021
Time: Available on-demand starting at 7:00 a.m. EST

A webcast of the event will be available at https://journey.ct.events/view/f11f4162-af9e-4b6d-b046-d0704649d31f for 90 days and will also be available on the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.

About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. PTG-300 is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional oral peptide interleukin-23 receptor antagonist candidates are in development: PN-235, in a Phase 1 study, and PN-232, in the late preclinical stage. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. The Company utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms.

Protagonist is headquartered in Newark, California. For further information, please visit http://www.protagonist-inc.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-the-hc-wainwright-global-life-sciences-conference-301237837.html

SOURCE Protagonist Therapeutics, Inc.

FAQ

When will Protagonist Therapeutics participate in the H.C. Wainwright Global Life Sciences Conference?

Protagonist Therapeutics will participate in the conference from March 9 to March 10, 2021.

What time is the fireside chat for Protagonist Therapeutics at the conference?

The fireside chat for Protagonist Therapeutics will start on March 9, 2021, at 7:00 a.m. EST.

Who will represent Protagonist Therapeutics at the H.C. Wainwright Conference?

Dinesh V. Patel, Ph.D., President and CEO, will represent Protagonist Therapeutics.

How can I access the Protagonist Therapeutics conference webcast?

The webcast will be available at the Protagonist website and can be accessed for 90 days after the event.

What are the key products in development by Protagonist Therapeutics?

Key products include PTG-300 for polycythemia vera and PTG-200 for Crohn's disease.